CN103159757A - 一类2,7-萘啶-1(2h)-酮的合成方法 - Google Patents
一类2,7-萘啶-1(2h)-酮的合成方法 Download PDFInfo
- Publication number
- CN103159757A CN103159757A CN2011104076773A CN201110407677A CN103159757A CN 103159757 A CN103159757 A CN 103159757A CN 2011104076773 A CN2011104076773 A CN 2011104076773A CN 201110407677 A CN201110407677 A CN 201110407677A CN 103159757 A CN103159757 A CN 103159757A
- Authority
- CN
- China
- Prior art keywords
- reaction
- hydrogen
- alkyl
- halogen
- perhaps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001308 synthesis method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 29
- 150000002431 hydrogen Chemical class 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 238000010189 synthetic method Methods 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 10
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical group ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 10
- 230000035484 reaction time Effects 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 238000005660 chlorination reaction Methods 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 claims description 3
- 150000005054 naphthyridines Chemical class 0.000 claims description 3
- 229940093916 potassium phosphate Drugs 0.000 claims description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 3
- 235000011009 potassium phosphates Nutrition 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 239000007810 chemical reaction solvent Substances 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Chemical group 0.000 claims 1
- REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 abstract description 7
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 abstract description 7
- 229940043355 kinase inhibitor Drugs 0.000 abstract description 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract description 6
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract description 4
- 150000005060 2,7-naphthyridines Chemical class 0.000 abstract description 2
- 239000000543 intermediate Substances 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 3
- PPXHSOAKGPXVNS-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-methyl-2-oxopyridine-3-carbonitrile Chemical compound O=C1C(C#N)=C(C)C=CN1C1=CC=C(F)C=C1 PPXHSOAKGPXVNS-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- -1 naphthyridines compounds Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 150000005055 1,5-naphthyridines Chemical class 0.000 description 1
- 150000005056 1,6-naphthyridines Chemical class 0.000 description 1
- ZFRUGZMCGCYBRC-UHFFFAOYSA-N 1h-1,8-naphthyridin-2-one Chemical class C1=CC=NC2=NC(O)=CC=C21 ZFRUGZMCGCYBRC-UHFFFAOYSA-N 0.000 description 1
- 150000005059 2,6-naphthyridines Chemical class 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- SIWQYLMSSMZJLU-VQHVLOKHSA-N 4-[(e)-2-(dimethylamino)ethenyl]-1-(4-fluorophenyl)-2-oxopyridine-3-carbonitrile Chemical compound O=C1C(C#N)=C(/C=C/N(C)C)C=CN1C1=CC=C(F)C=C1 SIWQYLMSSMZJLU-VQHVLOKHSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- HHOXWPCTCQMHNN-UHFFFAOYSA-N C1(=CC=CC=C1)I.[F] Chemical compound C1(=CC=CC=C1)I.[F] HHOXWPCTCQMHNN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical class ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000004768 bromobenzenes Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 150000008424 iodobenzenes Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (9)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110407677.3A CN103159757B (zh) | 2011-12-09 | 2011-12-09 | 一类2,7-萘啶-1(2h)-酮的合成方法 |
PCT/CN2012/070639 WO2013033981A1 (zh) | 2011-09-06 | 2012-01-20 | 一类2,7-萘啶衍生物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110407677.3A CN103159757B (zh) | 2011-12-09 | 2011-12-09 | 一类2,7-萘啶-1(2h)-酮的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103159757A true CN103159757A (zh) | 2013-06-19 |
CN103159757B CN103159757B (zh) | 2016-04-20 |
Family
ID=48583324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110407677.3A Active CN103159757B (zh) | 2011-09-06 | 2011-12-09 | 一类2,7-萘啶-1(2h)-酮的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103159757B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108473485A (zh) * | 2016-01-11 | 2018-08-31 | 默克专利股份公司 | 喹啉-2-酮衍生物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008109613A1 (en) * | 2007-03-05 | 2008-09-12 | Wyeth | Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors |
WO2011014515A1 (en) * | 2009-07-30 | 2011-02-03 | Irm Llc | 2, 7 -naphthyridin- 1 -one derivatives as syk kinase inhibitors |
CN101990539A (zh) * | 2008-02-01 | 2011-03-23 | Irm责任有限公司 | 作为激酶抑制剂的化合物和组合物 |
-
2011
- 2011-12-09 CN CN201110407677.3A patent/CN103159757B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008109613A1 (en) * | 2007-03-05 | 2008-09-12 | Wyeth | Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors |
CN101990539A (zh) * | 2008-02-01 | 2011-03-23 | Irm责任有限公司 | 作为激酶抑制剂的化合物和组合物 |
WO2011014515A1 (en) * | 2009-07-30 | 2011-02-03 | Irm Llc | 2, 7 -naphthyridin- 1 -one derivatives as syk kinase inhibitors |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108473485A (zh) * | 2016-01-11 | 2018-08-31 | 默克专利股份公司 | 喹啉-2-酮衍生物 |
CN108473485B (zh) * | 2016-01-11 | 2021-11-02 | 默克专利股份公司 | 喹啉-2-酮衍生物 |
Also Published As
Publication number | Publication date |
---|---|
CN103159757B (zh) | 2016-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2706235C2 (ru) | Композиции, пригодные для лечения расстройств, связанных с kit | |
ES2831749T3 (es) | Derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
Menichincheri et al. | Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor | |
Rew et al. | Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2–p53 interaction | |
AU2018255191B2 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
Shu et al. | Synthesis of a spiroindolinone pyrrolidinecarboxamide MDM2 antagonist | |
JP2022538774A (ja) | ピリジンカルバメート及びglun2b受容体調節因子としてのそれらの使用 | |
JP7029444B2 (ja) | Pde4阻害剤 | |
EA027082B1 (ru) | Производные имидазола в качестве ингибиторов фермента pde10a | |
JP2018537450A (ja) | Dnaメチルトランスフェラーゼ阻害剤としての新規化合物 | |
JP2021514997A (ja) | ピラゾロピリミジン誘導体及びその使用 | |
CN105732615A (zh) | Cdk激酶抑制剂 | |
Bryan et al. | Development of potent and selective pyrazolopyrimidine IRAK4 inhibitors | |
AU2020316056A1 (en) | Modulators of TREX1 | |
CN103159757A (zh) | 一类2,7-萘啶-1(2h)-酮的合成方法 | |
WO2015057200A1 (en) | Heteroaryl linked quinolinyl modulators of rorϒt | |
CN103936730A (zh) | 苯磺酰胺噻唑激酶抑制剂 | |
EP4010330A1 (en) | Quinoline derivatives as protein kinase inhibitors | |
CN103288823B (zh) | N,n’-芳基取代脲类化合物及其用途 | |
Chung et al. | Structure-activity relationship of 7-aryl-2-anilino-pyrrolopyrimidines as Mer and Axl tyrosine kinase inhibitors | |
JP2021527678A (ja) | Fgfr阻害剤、その製造方法および応用 | |
CN113461687B (zh) | 2,8-氮杂-[4,5]十螺环酮衍生物及其制备方法和用途 | |
WO2023138691A1 (en) | Fused heterocyclic compounds as modulators of ras signalling | |
CA3223874A1 (en) | Pyrimidine compounds for use as map4k1 inhibitors | |
CN117957232A (zh) | 氮杂吲唑大环化合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU SIMCERE PHARMACEUTICAL CO., LTD. Effective date: 20150625 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150625 Address after: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Applicant after: Jiangsu Simcere Pharmaceutical Research Company Limited Applicant after: Jiangsu Simcere Pharmaceutical Co., Ltd. Address before: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Applicant before: Jiangsu Simcere Pharmaceutical Research Company Limited |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160708 Address after: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Patentee after: Jiangsu Simcere Pharmaceutical Co., Ltd. Address before: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Patentee before: Jiangsu Simcere Pharmaceutical Research Company Limited Patentee before: Jiangsu Simcere Pharmaceutical Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201229 Address after: 570311 No. 2 Yaogu No. 3 Road, Xiuying District, Haikou City, Hainan Province Patentee after: Hainan Simcere Pharmaceutical Co.,Ltd. Address before: 210042 699 Xuanwu Road, Xuanwu District, Nanjing, Jiangsu -18 Patentee before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. |